Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 8/25/13

MomentumOptionsTrading.com Weekly Wrap for 8/25/13

11:30pm (EST)

 

1.  Market Summary 

2.  Rite Aid (RAD) is Good Medicine

3.  Earnings

4.  Weekly Wrap Portfolio Update 

5.  Week Ahead

 

(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section.)

 

= = = = = = = = = = = = = = =

 

1.  Market Summary  

“The bears came out attacking and pushed lower lows as the market suffered it worst weekly decline of the year.  The Dow fell triple-digits on back-to-back sessions for the first time since mid-June.  Over 40% of the S&P 500 companies are trading below their 50-day MA’s.  Things look bad but support is holding.

We don’t talk about the 10-Year Treasury Note Yield ($TNX) that often because we don’t invest in bonds.  However, we are watching the 3% level as the uptrend in bond yields continued last week.  A close above 3% could signal a correction “of 5%-10%” is coming as many of the suit-and-ties have been calling for all year.

TNX82513

The 10-year is trading at its highest level in two years and the surge in Thursday’s action was a result of China and Japan cashing out $40-$60 billion.  The two countries are the largest foreign holders of U.S. debt and it seems they are joining the crowd in thinking a September taper is coming and brace for an eventual end in the Fed’s bond buying.

We have been mentioning the smart money is pricing in an 80% chance (or greater) that the Fed Zombies will announce tapering in September but with last week’s pop in yields, we wouldn’t be surprised to see Bernanke send a message to curb the rise.  The jump in bond yields (and more talk of Fed tapering), along with Cisco’s cloudy outlook, and the turmoil in Egypt weight on the market but volume has been low and it could mean weaker players are folding their hands.

Gold is showing signs of life after struggling with its 50-day MA for much of the year.  The yellow metal made a solid move above $1,300 at the beginning of the month and tested $1,375 last week.  We have been bearish on gold for many months as we correctly called its drop below $1,200 in late July.  Since then we have said to look for a rebound back to $1,300 with $1,350-$1,375 coming into play on an overshoot.  The close above the $1,375 level is just below the 100-day MA and a close above this level will likely lead to a run to $1,400-$1,425.  A close back below $1,350 will likely get $1,325-$1,300 in play.

GOLD82513

Silver has shown a much stronger rebound and we mentioned a test to $22 could come if $20 held.  Following a brief test of $19 the prior week, silver busted through $20 and ran to a high of $23.40 on Friday.  We have been targeting $17.50 as a possible entry point to start adding silver again to our portfolio and we may or may not get that chance over the near-term as a run to $24-$26 could come on continued strength.  A close back below $22 would cool the momentum.

SILVER82513

Apple made a run to $500 after Carl Ichan revealed a stake in the company.  The shares strength helped the Nasdaq and broader markets from taking a possible nosedive.  If Apple remains strong and makes a run to $550, this should help the indexes heading into September.  However, if Apple pulls back to $470, the market could fall in tandem based on sympathy.

AAPL82513

The Financial Select Spiders (XLF, $20.02, down $0.03) have been holding $20 following the breakout above this level in early July.  Support has been strong at $20 and there is risk down to $19.75 and the 50-day MA, or $19.50, on continued softness.  As long as support holds, the Financial Spiders could test $21 and fresh highs on a breakout.

XLF82513

The Monday/ Friday closes have been mixed over the past few weeks as the bears have won the last 2 Monday’s on the Dow but the past two Friday’s have been split.  This Monday could be a good clue if the Dow closes lower but the losses have been mild as the Dow has fallen back to the bottom of its trading range. If the blue-chips give back another triple-digits to start the week, there is a good chance the June lows come into play.”  (from8/18/2013 Weekly Wrap…)

The bears continued their assault on the bulls last week as the market tested its August lows before making up some ground late in the week.

The Fed heads are clueless on where they want to go with QE (quantitative easing) as the zombies rubbed elbows in Jackson’s Hole while leaving more question marks than answers for Wall Street to figure out.

Meanwhile, a 3-hour trading halt on the Nasdaq brought back memories of flash crashes and fat fingers.  The volatility was typical for an August trading week as volume continues to be light while the big wigs wind down their summer vacations.  Friday’s rebound by the bulls was a nice bounce off the bottom of the trading ranges but they still have a little work to do before a rally cam be trusted.  (read more…)

The Dow advanced 47 points, or 0.3%, to finish at 15,010 on Friday.  The blue-chips tested the 15,000 level on Monday’s drop to 15,005 and we said there would be risk down to 14,800 if triggered.  Tuesday’s dip to 14,992 cracked the seal but the Dow rebounded to hit 15,074 before ending at 15,002.  Wednesday’s low was 14,880 as the bulls losing streak reached 6-sessions before Thursday’s bounce and close at 14,963.  The 15,000 level is now short-term resistance but was cleared on Friday’s pop to 15,025.  The next level of battle will occur at 15,200 and then 15,350-15,400.  We mentioned midweek a close below 14,800 would get 14,600 and the June lows in play.  The Dow started the week at 15,081 and fell 71 points, or 0.5%, by Friday’s close.  For the year, the blue-chips have advanced 1,906 points, or 14.6%.

DOW82513

The S&P 500 added a 6-pack, or 0.4%, to settle at 1,663.  The index came into the week just above 1,650 but broke below this level on Monday’s drop to 1,646.  It was the lowest close since July 9 and opened the door for a test to 1,625.  Tuesday’s action was all bull as the index reached a peak of 1,658 and held 1,650 by closing at 1,652.  Wednesday’s low reached 1,639 before a close at 1,642 and Thursday’s run to 1,659.  Although the index cleared 1,650, it still failed to close above its 50-day MA for a fourth-straight session.  However, Friday’s breakthrough cleared this level.  Resistance is at 1,675 and we have said to watch a close above 1,665 as confirmation higher prices could be back in the mix.  The S&P 500 came into Monday’s session at 1,655 and was up 8 points, or 0.5%, for the week.  For 2013, the index has gained 237 points, or 16.6%.

SPX82513

The Nasdaq jumped 19 points, or 0.5%, to end at 3,657.  Tech tried to hold 3,600 coming into the week and did for much of Monday’s session until the final hour of trading.  The close at 3,589 got 3,550-3,500 in the mix but Tuesday’s rebound to 3,625 and hold of 3,600 delayed the bears’ efforts.  We said the bulls needed to hold 3,625 in order to get 3,650 back in play and we knew the close at 3,613 would be short-lived as the index finished at 3,599.79 on Wednesday.  Thursday’s rebound to 3,638 was a good sign as 3,625 was cleared and Friday’s close above 3,650 again was bullish with the high coming in at 3,660.  The next 50 points will be crucial in deciding the next trend as the market winds down August and heads into September.  Resistance is at 3,675-3,700 while support is at 3,625-3,600.  The Nasdaq began the week at 3,602 and gained double-nickels (55 points), or 1.5%, by Friday’s closing bell.  Year-to-date, Tech has zoomed 638 points, or 21.1%.

NAS82513

The Russell 2000 popped 2 points higher, or 0.2%, to close at 1,038 on Friday.  The small-caps needed to clear 1,025 to start the week and was less than a point away but we knew the half-point pop to 1,024.61 was a bear omen.  The index gave back 11 points by the close and went out at 1,013.  We mentioned a close below 1,025 would get 1,000 in play but Tuesday’s rebound to 1,028 got the bulls excited.  The rally lasted less than 24 hours following a push to 1,030 as the Russell closed at 1,021 and back below 1,025 on Wednesday.  The index did hold its 50-day MA and that was a positive sign as Thursday’s surge to 1,038 looked good on paper.  However, we specifically said coming into the week the bulls would need to clear 1,040 and then 1,050 to reverse the trend and Monday will be an important day.  The Russell 2000 was at 1,024 before Monday’s open and managed to gain 14 points, or 1.4%, for the week.  YTD, the small-caps are up 189 points, or 22.2%.  We will talk more small-caps below.

RUT82513

The S&P 500 Volatility Index ($VIX, 13.98, down 0.78) came into the week at 14.37 and tripped 15 by Monday’s close, finishing at 15.10 after kissing a high of 15.20.  We said a close above this level would get 17.50 in the mix and Tuesday’s high was 16.22.  Wednesday’s 11% pop to 16.56 ended with a 7% gain to 15.94.  We have been warning once 15 to trigger to watch 17.50 for another possible leg lower on the S&P 500.  Thursday’s rebound pushed the VIX back below 15 and may have signaled a short-term top following Friday’s 5% pullback.  The bulls will need to get the VIX back below 13.50 this week or risk the bears running the VIX back up to the aforementioned resistance levels.

VIX82513

It was a fun ride for the blue-chips but all good streaks come to an end.  After 158 trading sessions, the Dow finally fell for four-straight days and a third-straight Monday.  The index had gone all year without a 4-game slide, a record to start any year, and beat the old record of 143 consecutive sessions set in 1954 by 3 weeks.

The last time the Dow had lost 4-straight was in December 2012 when the index fell five-straight over Christmas break and 373 points.  The just ended 6-session losing streak cost the Dow roughly 625 points and the index recovered a little over 100 points on Thursday and Friday.

We talked about Fibonacci Retracements last Tuesday because we felt the indexes were holding the bottoms of their trading ranges.  Fibonacci retracement levels are ratios used to identify potential reversal levels following new highs or breakouts in the market or a stock.  The most widely used Fibonacci Retracements are 61.8% and 38.2%.

The other common retracement level is 23.6%, another Fib number, and 50%, a Dow Theory throw-in number as the major indexes or stocks often retrace half their prior move.

Technicians say retracements of 23.6% are relatively minor setbacks.  Retracements in the 38.2%-50% range are considered moderate and pullbacks in the 61.8% range are often referred to as “golden retracements”.  A 100% retracement can also occur after peaks and are considered trend changes or corrections if they deepen.

The good news for the bulls is that rebounds can be expected once these Fibonacci levels are reached for a potential bullish reversal.

For the S&P 500, the 50% retracement level from the June low of 1,560 to the early August high of 1,709 is around 1,635 and Wednesday’s low was 1,639.  The 61.8% level is at 1,625 or so and a level we have talked about.

The Nasdaq hit a low of 3,294 in June and peaked at 3,694 during the first week of the month.  It was a 400-point advance and this one is easy.  A 23.6% retracement is roughly 95-100 points and 3,589 check-in as the low last Monday.  If you take 100 points off the high of 3,694 you get 3,594 so Tech came within 5 points of tagging this number.  The 38.2% retracement level is around 3,550 and a level we have talked about if support at 3,600 fails.

The Russell 2000 bottomed at 940 in June and maxed out at 1,063 in early August for a gain of 123 points.  If you take 50% of that number you get 61.5 points.  This would put the Russell right around the 1,000 level.  Last Monday’s low was 1,013.  Pretty close, huh?

The Dow’s June low was 14,551 and the high was 15,658 on the second day of August.  This is a surge of 1,107 points so half is 553.5 points.  If we use the Fibonacci level of 61.8%, it would be roughly 680 points.  Off the high, this would put the blue-chips at 14,978.  Sometimes these fib levels get stretched to 65% and the recent low on the Dow was 14,880 last Wednesday.  The 50% level is 15,100 and served as prior support.  This levels need to clear this week.

As you can see, we could have summed things up by saying the Russell and S&P have retraced 50% of their Fibonacci levels while the Nasdaq has bounced off its 23.6% fib level and the Dow is rebounding off its 61.8% fib level.

The Monday/ Friday closes are still mixed with 3-straight down Monday’s with this prior Friday being up.  This is another reason why the Dow needs to try and get a positive close this Monday (and Friday, of course).  Another lower M/F could suggest further weakness ahead if the rebounds fades this week.

The small-caps showed some solid strength following the bounce off the lows and have been one of OUR leading indicators in calling the market’s direction all year long.  They still have some work to do but with the 1,000 level holding it was a good sign.  Another good clue we use from time-to-time is the Dow Transports.  The index surged through its 50-day MA last week and could push 6,550-6,600 on continued strength.  This would be a bullish sign.

TRAN82513

The market is holding the bottom of its July trading range and a retest could lead to the June lows: Dow 14,551; S&P 1,560; Nasdaq 3,294; Russell 940 – if the bulls stumble out of the gate.  The VIX reached a peak of 18.58 in late June.  If the golden Fibs don’t hold then these levels will likely be tested and is the bearish case.

If the bulls clear the first and second waves of resistance, the market could be setting up for a test to the top of the trading ranges and/ or new highs again going into September.  The last week of August is usually the strongest of the month but volume will once gain be light as a feather.

As we head to press, futures look like this:  Dow futures are up 2 points to 114,992 while the S&P 500 futures are down a fifth of a point to 1,661.20.  The Nasdaq 100 futures are advancing a quart point to 3,121.50.

 

= = = = = = = = = = = = = = =

 

2.  Rite Aid (RAD) is Good Medicine

By Michael Bryant

 

Demand for pharmaceuticals will likely increase as Baby Boomers age and healthcare reform kicks in.  The drugstore industry, currently about $250 billion in the U.S., will likely rise as a result and Rite Aid (RAD, $3.43, down $0.01) stands to benefit.

Charta82513

Founder Alexander Grass’ father ran a business manufacturing hats and caps but died when Grass was 9.  Since the business had a lot of debt, the family was left with little income in the middle of the Great Depression.  After the family moved to Miami Beach, Florida in 1936, Grass worked a number of small jobs, including at a local drugstore.  In early 1945, he joined the Navy to help out in the war effort, but the war ended before he even finished boot cap.  He was discharged in August of 1946, and went on to obtain a law degree from the University of Florida Law School in 1949 using the G.I. Bill to help pay for school.

After marrying, he moved back to Pennsylvania to pursue a legal career in tax law with the Internal Revenue Service, but a scandal within the IRS thwarted that plan.  Imagine that, a scandal at the IRS.

He started working for Lehrman & Sons, his father-in-law’s grocery distribution company in Pennsylvania.  Grass helped increase sales at the business by adding more appealing programs and replacing most of the sales force.  Noticing a lack of stores selling competitively priced health and beauty products in Pennsylvania, he launched Rack Rite Distributors as a subsidiary of Lehrman & Sons in 1958.  The subsidiary rented and stocked racks of non-grocery items for grocery stores.  In 1962, Rack Rite opened its first store, Thrif D Discount Center, in Scranton, Pennsylvania as a health and beauty aids store but no pharmacy.  This store would become the birthplace of Rite Aid.

In its first year, the store had sales of more than a quarter-million dollars, far exceeding expectations.  After opening the third Thrif D Discount Center store, the retail stores were making more money than the other two businesses combined.  At that point, Grass decided to focus mainly on the retail health and beauty aid business.  By 1965, the Thrif D chain had 21 outlets, and added a pharmacy in their 22nd store.  In 1968, the chain changed its name to Rite Aid after the name of their lead product.  Its parent company, Lehrman & Sons, reorganized and became Super Rite Foods, a subsidiary of Rite Aid.  Rite Aid then went public on the American Stock Exchange at $25 a share.  With increased profits from prescription sales, the chain moved to the New York Stock Exchange in 1970.

In 1969, it purchased rival chain the Daw Drug Company, which doubled Rite Aid’s size.  By 1981, it operated 267 locations in 10 states and was the 3rd largest drugstore in the United States.  In 1983, its revenues exceeded $1 billion annually.  Also that year, it spun off Super Rite Foods.  A 420-store acquisition along the east coast and an acquisition of Ohio-based drugstore Gray Drug expanded Rite Aid to over 2,000 stores in 1987.  Through many more acquisitions, it became the number one drugstore in the country in store count and the number two drugstore in terms of revenue in 1995.  That year, Alexander Grass retired as chairman and chief executive.

Martin Grass, son of Alexander Grass, became CEO and Chairman.  Martin Grass pursued a strategy of rapid expansion and acquisition, but ended up hurting the chain and the brand.  He was fired by the company in 1999, after he was connected to a $1.6 billion accounting scandal that nearly destroyed the company.  He was convicted of overstating Rite Aid’s earnings during the 1990s and sentenced to eight years in federal prison.

In an attempt to turn the company around, Rite Aid partnered with General Nutrition Companies (GNC), which makes vitamin and mineral supplements, in January 1999, bringing GNC mini-stores within Rite Aid pharmacies.  Such stores saw a boost in sales.  Rite Aid operated 1,726 GNC mini-stores as of February 28, 2009 and plans to open an additional 626 stores by December 2014.

In August 2007, Rite Aid acquired approximately 1,850 Brooks/Eckerd Stores throughout the United States.  In December of that year, it was reported that Rite Aid had record-breaking losses that year, despite the acquisition of Brooks and Eckerd chains.  The following fiscal quarter saw an increase in revenue but a sharp fall in net income.  Shares fell over 75% between September 2007 and September 2008, partly due to the Credit Crisis.

Chartb82513

The company’s products can be separated into front end products and prescription drugs.  Front end products include over-the-counter medications, cosmetics, greeting cards, photo processing, and other products.  They have a higher profit margin than prescription drugs.  In fiscal 2009, front-end products represented 32.8% of the company’s revenue.  But generic drugs also produce higher profit margins than brand-name drugs.  As $31 billion of brand-name drugs lose patent, the company may see improved margins.

A partnership with drugstore.com in June 1999 allowed customers of Rite Aid to place medical prescription orders online for same-day, in-store pickup, an important step in its digital strategy.  Rite Aid got the rights to prescriptions ordered online for pick up at a Rite Aid store, and Drugstore.com received $10 million from Rite Aid.  Drugstore.com also was paid to market Rite Aid prescriptions.

In the year ending February 28, 2010, the company earned $26.2 billion in revenues, up 7.8% from the year earlier.  However, its net loss grew from $1.1 billion to $2.9 billion over the same time period.  Between August 2009 and February 2010, as part of cost-cutting measures, it laid off 6,500 employees, or 6% of its workforce.

In December 2012, the company recorded its first quarterly profit in more than five years, helped by growth in the number of prescriptions filled and higher comparable sales of general merchandise at its stores.  The company reported net income of $60.5 million, or 7 cents a share, for the 3rd quarter ending December 1st, compared to a loss of $54.5 million, or -6 cents a share, in the same period a year ago.  Analysts on average expected a loss of 3 cents a share.

Walgreen (WAG) operates the largest chain of drug stores in the US, with over 8,000 locations in the United States.   CVS Caremark (CVS) is second and Rite Aid is third.  But based on pharmacy sales, CVS is #1 followed by Walgreen, Express Scripts (ESRX), Walmart (WMT) pharmacy, and Rite Aid.  There has been speculation that Walmart might buy Rite Aid, but so far Walmart has declined interest.  Below is the market share of the top five drugstores based on pharmacy sales.

CVS

WAG

ESRX

WMT

        RAD

22.8%

15.5%

11.9%

6.5%

6.4%

On June 20, 2013, Rite Aidreported its third straight quarterly profit, as generic drugs and expense reductions continued to help the drugstore chain.  It earned $91 million, or 9 cents per share, after paying preferred dividends, in the quarter that ended June 1.  That compares to a loss of $30.7 million, or -3 cents per share, in last year’s quarter, when Rite Aid booked a $21 million charge for lawsuit settlements.  Revenue fell about 3% to $6.29 billion from $6.47 billion a year ago.  Analysts expected, on average, earnings of 8 cents per share on about $6.29 billion in revenue.

The drugstore chain said that it now expects fiscal 2014 earnings of between a penny and 16 cents per share.  That is down from its forecast in April for earnings ranging between 4 cents and 20 cents per share.  The company still expects revenue of between $24.9 billion and $25.3 billion.  Analysts expect, on average, earnings of 17 cents per share on $25.24 billion in revenue.

According to the 13F SEC filing for the 2nd quarter ended June 30th, billionaire hedge fund manager David Einhorn’s Greenlight Capital, which overseas $8 billion, acquired 20.2 million shares of Rite Aid during the quarter.  According to the filing, he bought shares three times:

  • 13,052,600      shares at $2.86 for a total of $37,330,000
  • 2,872,300      shares at $2.86 for a total of $8,215,000
  • 4,275,100      shares at $2.86 for a total of $12,227,000

A few weeks ago, Rite Aid released same-store sales for the month of July.  For the four weeks ended July 27th, same-store sales increased 1.3% from the prior-year period.  July front-end same-store sales rose 0.7%; pharmacy same-store sales rose 1.6%; and prescription same-store sales rose 0.4% from the prior-year period.  Total drugstore sales for the four-week period increased 0.9% to $1.898 billion compared to $1.881 billion for the same period last year.  Prescription sales at comparable stores accounted for 67.7% of those sales.

However, same-store sales for the 21-week period ended July 27th fell 1.2% from the prior-year period.  Front-end same-store sales rose 0.4% while pharmacy same store sales fell 1.9%. Prescription sales at comparable stores were flat compared to the prior-year period.  Total drugstore sales fell 1.5% with sales of $10.089 billion compared to $10.247 billion for the same period last year.  Prescription sales represented 67.5% of those sales.

The company reports 2nd quarter earnings on Thursday, September 19th before the bell.  Analysts estimate the company will earn $0.02 per share on $6.23 billion.  As shown in the graphs below, analysts’ revenue and earnings estimates seem easily attainable from previous quarter.  In fact, the earnings estimate seems easy to beat.

Chartc82513

 

Friday’s September call options, the 3.50 and 4.00 strike prices have the highest open interest.

Rite Aid recently stated that seasonal flu shots are now available at all of its more than 4,600 pharmacies across the United States.  Flu season is an annually-recurring time period characterized by the prevalence of outbreaks of influenza (flu).  The season occurs during the cold half of the year.  In the United States, the flu season is considered October through May, and activity usually peaks in February.  Last year, the company gave out more than 2 million flu vaccines.  Flu sales helped the drugstore chain post a 0.3% increase in same-store sales for the month of January.  The shots were $29.99 each last year and are covered by many insurance plans, including Medicare.

Chartd82513

Charte82513

At $3+, the stock is slightly above its high target of $3.50 made by the 6 analysts recorded by Thomson/First Call.  Mean target is $2.89, median target is $3.05, and low target is $2.00.  Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 2.4, unchanged from a week ago.

 

Current Month

Last Month

Two Months Ago

Three Months Ago

Strong Buy

1

1

1

1

Buy

2

3

3

3

Hold

3

4

4

4

Underperform

0

0

0

0

Sell

0

0

0

0

We like the company as a longer-term investment.

 

= = = = = =

 

3.  Earnings  

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter.  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are from 8/23/13 close)

By Catherine Tierney

 

Monday

ANFI, CO, CWTR, CRDS, DCIN, Greif (GEF, $57.21, up $1.06), Isle of Capri Casinos (ISLE, $7.81, up $0.14), KNOP, OXM, PNX, TWGP, Qihoo 360 Technologies (QIHU, $73.13, up $0.27)

 

Tuesday

ARAY, ADEP, AVAV, AVGO, BWS, DCI, DSW, DY, HEI, ISS, LDK, Movado Group (MOV, $40) September 40 calls wide bid/ ask, QIWI, Sanderson Farms (SAFM, $71, up $0), Tiffany & Co (TIF, $82, up $0.50), Wet Seal (WTSL, $3.85, up $0.02), WMS, Work Day (WDAY, $75.76, up $0.80) September 80 calls / September 70 puts

 

Wednesday

ACET, AMAP, CWST, CHS, CHOP, DLA, GMAN, Guess (GES, $28.21, down $0.57), JOY, SeaDrill (SDRL, $43.61, up $0.84), TLYS, ZLC

 

Thursday

FLWS, AMSWA, BRLI, BONA, CPB, COCO, ESL, FRED, GCO, JASO, Krispy Kreme Doughnuts (KKD, $22.60, down $0.02), MEI, PLL, Salesforce.com (CRM, $43.59, down $0.16) September 50 calls, GAME, SIG, TD,

 

Friday

SOL, YGE

 

= = = = = = = = = = = = =

 

4.  Weekly Wrap Covered Call Portfolio Update (Closing prices as of 8/23/13)

Our Weekly Wrap Closed Trade Track Record for 2013 is 31-3 (75-5, overall since the start of 2011).

Special Notice:  Psychemedics (PMD, $12.74, down $0.43) was closed late Friday as our Hard Stop of $12.75 was triggered after shares traded to a low of $12.35.  Shares reached a 52-week high of $13.40 in the morning before the late-day selloff on no news.  The trade made us 11% and we will keep shares on our Watch List.

 

Royal Bank of Scotland (RBS, $10.80, up $0.06)

Original Entry Price:  $10.35 (7/23/13)

Lowered Price from Selling Options:  $10.35

Exit Target:  $14

Return:  4%

Stop Target:  $10.40, raise to $10.50 (Hard Stop)

Action:  Shares traded to a low of $10.47 on Monday but held $10.50 before kissing $10.72 on Tuesday and closing at $10.66.  We mentioned during the week in our Daily the stock needed to clear $10.75 on the close or faced risk down to $10.40.  Wednesday’s low was $10.43 but shares rebounded on Thursday to close at $10.74.  Friday’s high reached $10.85 and a close above $11 would be bullish.  Support is at $10.40.  We have moved the Hard Stop up to $10.50.

RBS82513

Rite-Aid (RAD, $3.43, down $0.01)

Original Entry Price:  $2.90 (7/23/13)

Lowered Price from Selling Options:  $2.90

Exit Target:  $6

Return:  18%

Stop Target:  $3.25, raise to $3.35 (Hard Stop)

Action:  Shares pushed $3.60 to start the week but traded down to $3.35 and closed at $3.40.  Tuesday’s pop to $3.50 and close at $3.48 signaled short-term resistance as shares struggled with this area the remainder of the week.  We have a near-term target of $4 and a longer-term target of $5 on the stock.  Support is at $3.20.  We have a Hard Stop at $3.25 and we are going to raise it to $3.35.  This was the low last week on Monday and Wednesday.

RAD82513

Galena Biopharma (GALE, $2.36, up $0.18)

Original Entry Price:  $2.12 (7/8/13)

Lowered Price from Selling Options:  $2.12

Exit Target:  $5

Return:  11%

Stop Target:  $1

Action:  Gale tested support at $1.90 on Monday and $1.91 on Tuesday before the midweek surge to $2.23 and close at $2.14 on heavy volume.  The company announced it would be expanding its relationship with NeuVax, a European company.  Shares added 4 cents on Thursday before Friday’s surge to $2.47.  The 52-week high is at $3 and could be challenged on further momentum.  Support will now try to hold at $2.20, a level that represented prior resistance.

GALE82513

Exact Sciences (EXAS, $11.87, down $0.14)

Original Entry Price:  $13.55 (6/11/13)

Lowered Price from Selling Options:  $13

Exit Target:  $16+

Return:  -9%

Stop Target:  $10

Action:  Shares traded down to $11.72 before clearing $12 and reaching to a high of $12.31 before settling at $12.27 to start the week.  Tuesday’s high was also $12.31 but shares lost a nickel after testing a low of $12.10.  Wednesday’s low was $11.95 but shares held $12, finishing at $12.04.  Thursday’s run to $12.25 faded as shares tested $11.86 before Friday’s drop to $11.55 and the 100-day MA.  There is further risk down to $11.  A close back above $12.50 would be bullish and where we would sell another call option.

EXAS82513

We recommended buying Exact Sciences at $13.55 on 6/11/13.  On 7/11/13 we sold the August 15 calls for 55 cents which lowered our cost basis to $13.

 

Pizza Inn Holdings (PZZI, $7.31, up $0.12)

Original Entry Price:  $5.40 (6/11/13)

Lowered Price from Selling Options:  $5.40 (no options available)

Exit Target:  $10+

Return:  35%

Stop Target:  $6.75, raise to $6.95 (Hard Stop) 

Action:  Shares fell below $7 to start the week and kissed $6.90 before holding $7.  Shares traded higher over the next 2 session and reached $7.25 midweek that was matched on Thursday.  Friday’s high was $7.42 and short-term resistance remains at $7.50.  A close above $8 would be bullish.  Support is at $7 and we have moved our Hard Stop to $6.95.

PZZI82513

Trades on HOLD (7):  DryShips (DRYS, $2.25, up $0.08), AKS Steel Holding (AKS, $3.55, up $0.08), Rare Element Resources (REE, $2.15, up $0.02), Rambus (RMBS, $8.44, down $0.03), Bebe Stores (BEBE, $5.96, down $0.05),  Vivus (VVUS, $12.42, up $0.02), Dendreon (DNDN, $2.91, down, $0.28),

 

= = = = = = = = = = = = = = =

 

5.  Week Ahead 

Here is a chart of the events for the week ahead:

Ecocal82513_001

 

Special Notice:  Our next issue of the Weekly Wrap will be out on Monday, September 1, before midnight.  The market will be closed that day and we will be doing a shorter version of the Weekly Wrap as we enjoy the holiday weekend as well.  If we have any New Trades or Alerts, we will send them out during market hours and we will be in the office until Friday’s closing bell, as usual.

 

 

 

 

 

Scroll to Top